カテゴリ： Allied Market Research, 世界, 医療/バイオ

オピオイド誘発性便秘症（OIC）治療薬のグローバル市場（2021～2031）：μオピオイド受容体拮抗薬、クロライドチャネル2活性剤、その他

■ 英語タイトル：Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), By Prescription Type (Over The Counter Drugs, Prescribed Drugs), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23MC087）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23MC087
■ 発行日：2023年1月
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：359
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[オピオイド誘発性便秘症（OIC）治療薬のグローバル市場（2021～2031）：μオピオイド受容体拮抗薬、クロライドチャネル2活性剤、その他]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の調査資料では、2021年には1,105.71百万ドルであった世界のオピオイド誘発性便秘症（OIC）治療薬市場規模が2031年には1,785.01百万ドルへ及び、2022年から2031年の間にCAGR 4.9％増加すると推測されています。本調査資料では、オピオイド誘発性便秘症（OIC）治療薬の世界市場を広く調査・分析し、イントロダクション、エグゼクティブサマリー、市場概要、薬物種類別（μオピオイド受容体拮抗薬、クロライドチャネル2活性剤、その他）分析、処方種類別（一般医薬品、処方箋医薬品）分析、流通チャネル別（病院内薬局、オンラインプロバイダー、ドラッグストア・小売薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米/中東・アフリカ）分析、競争状況、企業情報などを整理しました。並びに、本資料に記載されている企業として、AstraZeneca plc、cosmo pharmaceuticals、Dr. Reddy’s Laboratories Ltd.、Mallinckrodt plc、Novartis AG、Teva Pharmaceutical Industries Ltd.、Shionogi & Co., Ltd.、Bausch Health Companies Inc.、Merck & Co., Inc.、Takeda Pharmaceutical Company Limitedなどが含まれています。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のオピオイド誘発性便秘症（OIC）治療薬市場規模：薬物種類別
- μオピオイド受容体拮抗薬の市場規模
- クロライドチャネル2活性剤の市場規模
- その他オピオイド誘発性便秘症（OIC）治療薬の市場規模
・世界のオピオイド誘発性便秘症（OIC）治療薬市場規模：処方種類別
- 一般医薬品の市場規模
- 処方箋医薬品の市場規模
・世界のオピオイド誘発性便秘症（OIC）治療薬市場規模：流通チャネル別
- 病院内薬局チャネルの市場規模
- オンラインプロバイダーチャネルの市場規模
- ドラッグストア・小売薬局チャネルの市場規模
・世界のオピオイド誘発性便秘症（OIC）治療薬市場規模：地域別
- 北米のオピオイド誘発性便秘症（OIC）治療薬市場規模
- ヨーロッパのオピオイド誘発性便秘症（OIC）治療薬市場規模
- アジア太平洋のオピオイド誘発性便秘症（OIC）治療薬市場規模
- 中南米/中東・アフリカのオピオイド誘発性便秘症（OIC）治療薬市場規模
・競争状況
・企業情報

オピオイド誘発性便秘症（OIC）治療薬市場は2021年に11億571万ドル、2031年には17億8501万ドルに達すると推定され、2022年から2031年までの年平均成長率は4.9%となる見込みです。
オピオイド誘発性便秘症（OIC）は、鎮痛薬の一種であるオピオイドの一般的な副作用です。オピオイド誘発性便秘症（OIC）は、オピオイドが消化管の筋肉の動きを鈍らせ、排便が困難になることで起こります。オピオイド誘発性便秘症（OIC）の症状には、排便回数が少ない、便が硬い、便が出にくいなどがあります。オピオイド誘発性便秘症（OIC）治療薬市場とは、オピオイドの使用によって引き起こされる便秘を管理するために使用される様々な薬剤や治療法を指します。モルヒネ、コデイン、ヒドロコドンなどのオピオイド薬は便秘を引き起こします。

オピオイド誘発性便秘症（OIC）治療薬市場の成長を促す主な要因は、疼痛管理のためのオピオイド使用の増加、高齢者人口の増加、オピオイド誘発性便秘症（OIC）の有病率の増加です。例えば、National Library of Medicine 2022に掲載された論文によると、オピオイド誘発性便秘症（OIC）の有病率は2021年に15～81％を占めると報告されており、これが市場の成長を促進しています。さらに、高齢者人口は慢性疾患や疼痛障害に罹患しやすいため、高齢者人口の増加が市場の成長に寄与すると予想されます。例えば、世界保健機関（WHO）の報告書（2022年）によると、60歳以上の高齢者数は2020年の10億人から14億人に増加するとされており、高齢者人口の増加が市場の成長を促進すると予測されています。

また、高齢者人口には癌性疼痛などの疼痛疾患が多く、その結果、オピオイドの使用が増加し、便秘が蔓延する可能性があります。例えば、National Institute of Health 2021に掲載された論文によると、2020年には世界中で65歳以上の患者の4～9%が鎮痛のために処方オピオイド薬を使用すると報告されており、市場の成長を促進しています。しかし、オピオイド誘発性便秘症（OIC）を治療するための新規医薬品のコストが高く、償還政策が不利であることが、市場の成長を抑制する要因となっています。

さらに、研究開発活動の増加、規制当局の承認の増加、オピオイド誘発性便秘症（OIC）研究への支出の増加は
市場の主要プレイヤーに有利な機会を提供すると予想される要因です。さらに、オピオイド誘発性便秘症（OIC）治療のための新規治療薬に対する需要の増加が、市場の成長をさらに促進すると予想されます。

世界のオピオイド誘発性便秘症（OIC）治療薬市場は、薬剤タイプ、処方タイプ、流通チャネル、地域に区分されます。
薬剤タイプ別では、mu-オピオイド受容体拮抗薬、クロライドチャネル-2活性化薬、その他に分類されます。
処方タイプ別では、市販薬と処方薬に分類されます。
流通チャネル別では、病院薬局、オンラインプロバイダー、ドラッグストア、小売薬局に分類されます。
地域別では、北米（米国、カナダ、メキシコ）、欧州（ドイツ、フランス、英国、イタリア、スペイン、その他欧州）、アジア太平洋（日本、中国、オーストラリア、インド、韓国、その他アジア太平洋）、LAMEA（ブラジル、南アフリカ、サウジアラビア、その他LAMEA）に市場を分けて分析しています。

世界のオピオイド誘発性便秘症（OIC）治療薬市場で事業を展開する主な主要企業は、AstraZeneca、Bausch Health Companies Inc.、Cosmo pharmaceuticals、Dr. Reddy’s Laboratories Ltd.、Mallinckrodt plc、Merck & Co., Inc.、Novartis AG、武田薬品工業株式会社、Teva Pharmaceutical Industries Ltd.、塩野義製薬株式会社などです。

〈ステークホルダーにとっての主なメリット〉
・オピオイド誘発性便秘症（OIC）治療薬の市場機会を特定するため、2021年から2031年までの市場セグメント、現在の動向、予測、市場ダイナミクスを定量的に分析します。
・オピオイド誘発性便秘症（OIC）治療薬市場に関する2021年から2031年までの分析結果をまとめました。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・オピオイド誘発性便秘症（OIC）治療薬市場のセグメンテーションを詳細に分析し、市場機会を把握します。
・各地域の主要国は、世界市場への収益貢献度に応じてマッピングされています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・オピオイド誘発性便秘症（OIC）治療薬の地域別および世界市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
薬剤タイプ別
ミューオピオイド受容体拮抗薬
クロライドチャネル-2活性化薬
その他

処方タイプ別
市販薬
処方薬

流通チャネル別
病院薬局
オンラインプロバイダー
ドラッグストアおよび小売薬局

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
AstraZeneca plc
cosmo pharmaceuticals
Dr. Reddy’s Laboratories Ltd.
Mallinckrodt plc
Novartis AG
Teva Pharmaceutical Industries Ltd.
塩野義製薬株式会社
Bausch Health Companies Inc.
Merck & Co., Inc.
武田薬品工業株式会社

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Bargaining power of suppliers
3.3.2. Bargaining power of buyers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Intensity of rivalry
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of opioid induced constipation (OIC) cases
3.4.1.2. Rise in administration of opioids for cancer and non-cancer pain
3.4.1.3. Rise in the availability of effective opioid induced constipation (OIC) drugs

3.4.2. Restraints
3.4.2.1. Side effects associated with medications used for opioid induced constipation

3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets

3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Mu-opioid Receptor Antagonists
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Chloride Channel-2 Activators
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Others
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
CHAPTER 5: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Over The Counter Drugs
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Prescribed Drugs
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
CHAPTER 6: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital Pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Online Providers
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Drug Store and Retail Pharmacies
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Drug Type
7.2.3. Market size and forecast, by Prescription Type
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Drug Type
7.2.5.1.3. Market size and forecast, by Prescription Type
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Drug Type
7.2.5.2.3. Market size and forecast, by Prescription Type
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Drug Type
7.2.5.3.3. Market size and forecast, by Prescription Type
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Drug Type
7.3.3. Market size and forecast, by Prescription Type
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Drug Type
7.3.5.1.3. Market size and forecast, by Prescription Type
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Drug Type
7.3.5.2.3. Market size and forecast, by Prescription Type
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Drug Type
7.3.5.3.3. Market size and forecast, by Prescription Type
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Drug Type
7.3.5.4.3. Market size and forecast, by Prescription Type
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Drug Type
7.3.5.5.3. Market size and forecast, by Prescription Type
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Drug Type
7.3.5.6.3. Market size and forecast, by Prescription Type
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Drug Type
7.4.3. Market size and forecast, by Prescription Type
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Drug Type
7.4.5.1.3. Market size and forecast, by Prescription Type
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. China
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Drug Type
7.4.5.2.3. Market size and forecast, by Prescription Type
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. Australia
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Drug Type
7.4.5.3.3. Market size and forecast, by Prescription Type
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. India
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Drug Type
7.4.5.4.3. Market size and forecast, by Prescription Type
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Drug Type
7.4.5.5.3. Market size and forecast, by Prescription Type
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Drug Type
7.4.5.6.3. Market size and forecast, by Prescription Type
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Drug Type
7.5.3. Market size and forecast, by Prescription Type
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Drug Type
7.5.5.1.3. Market size and forecast, by Prescription Type
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Drug Type
7.5.5.2.3. Market size and forecast, by Prescription Type
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Drug Type
7.5.5.3.3. Market size and forecast, by Prescription Type
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Drug Type
7.5.5.4.3. Market size and forecast, by Prescription Type
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2021
CHAPTER 9: COMPANY PROFILES
9.1. AstraZeneca plc
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Bausch Health Companies Inc.
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. cosmo pharmaceuticals
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. Dr. Reddy’s Laboratories Ltd.
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Mallinckrodt plc
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.6. Merck & Co., Inc.
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Novartis AG
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Shionogi & Co., Ltd.
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Takeda Pharmaceutical Company Limited
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. Teva Pharmaceutical Industries Ltd.
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance

LIST OF TABLES
TABLE 01. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 02. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR MU-OPIOID RECEPTOR ANTAGONISTS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 03. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR CHLORIDE CHANNEL-2 ACTIVATORS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 04. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 05. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 06. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR OVER THE COUNTER DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 07. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR PRESCRIBED DRUGS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 08. GLOBAL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 09. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 10. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 11. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 12. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
TABLE 13. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 14. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 15. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 16. NORTH AMERICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 17. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 18. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 19. U.S. OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 20. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 21. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 22. CANADA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 23. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 24. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 25. MEXICO OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 26. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 27. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 28. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 29. EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 30. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 31. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 32. GERMANY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 33. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 34. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 35. FRANCE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 36. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 37. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 38. UK OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 39. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 40. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 41. ITALY OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 42. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 43. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 44. SPAIN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 45. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 46. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 47. REST OF EUROPE OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 48. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 49. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 50. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 51. ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 52. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 53. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 54. JAPAN OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 55. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 56. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 57. CHINA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 58. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 59. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 60. AUSTRALIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 61. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 62. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 63. INDIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 64. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 65. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 66. SOUTH KOREA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 67. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 68. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 69. REST OF ASIA-PACIFIC OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 70. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 71. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 72. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 73. LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
TABLE 74. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 75. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 76. BRAZIL OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 77. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 78. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 79. SAUDI ARABIA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 80. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 81. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 82. SOUTH AFRICA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 83. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DRUG TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 84. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY PRESCRIPTION TYPE, 2021-2031 (REVENUE, $MILLION)
TABLE 85. REST OF LAMEA OPIOID INDUCED CONSTIPATION (OIC) DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 (REVENUE, $MILLION)
TABLE 86. ASTRAZENECA PLC: KEY EXECUTIVES
TABLE 87. ASTRAZENECA PLC: COMPANY SNAPSHOT
TABLE 88. ASTRAZENECA PLC: PRODUCT SEGMENTS
TABLE 89. ASTRAZENECA PLC: PRODUCT PORTFOLIO
TABLE 90. BAUSCH HEALTH COMPANIES INC.: KEY EXECUTIVES
TABLE 91. BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
TABLE 92. BAUSCH HEALTH COMPANIES INC.: PRODUCT SEGMENTS
TABLE 93. BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
TABLE 94. COSMO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 95. COSMO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 96. COSMO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 97. COSMO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 98. COSMO PHARMACEUTICALS: KEY STRATERGIES
TABLE 99. DR. REDDY’S LABORATORIES LTD.: KEY EXECUTIVES
TABLE 100. DR. REDDY’S LABORATORIES LTD.: COMPANY SNAPSHOT
TABLE 101. DR. REDDY’S LABORATORIES LTD.: PRODUCT SEGMENTS
TABLE 102. DR. REDDY’S LABORATORIES LTD.: PRODUCT PORTFOLIO
TABLE 103. MALLINCKRODT PLC: KEY EXECUTIVES
TABLE 104. MALLINCKRODT PLC: COMPANY SNAPSHOT
TABLE 105. MALLINCKRODT PLC: PRODUCT SEGMENTS
TABLE 106. MALLINCKRODT PLC: PRODUCT PORTFOLIO
TABLE 107. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 108. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 109. MERCK & CO., INC.: PRODUCT SEGMENTS
TABLE 110. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 111. NOVARTIS AG: KEY EXECUTIVES
TABLE 112. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 113. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 114. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 115. NOVARTIS AG: KEY STRATERGIES
TABLE 116. SHIONOGI & CO., LTD.: KEY EXECUTIVES
TABLE 117. SHIONOGI & CO., LTD.: COMPANY SNAPSHOT
TABLE 118. SHIONOGI & CO., LTD.: PRODUCT SEGMENTS
TABLE 119. SHIONOGI & CO., LTD.: PRODUCT PORTFOLIO
TABLE 120. TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY EXECUTIVES
TABLE 121. TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
TABLE 122. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT SEGMENTS
TABLE 123. TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
TABLE 124. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
TABLE 125. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
TABLE 126. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
TABLE 127. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • めまい治療のグローバル市場（2021〜2031）：末梢性めまい、中枢性めまい
  • 原発性胆汁性胆管炎（PBC）治療薬のグローバル市場（2023-2032）：一次薬剤、二次薬剤
  • 筋骨格系障害（MSD）治療薬のグローバル市場（2023-2032）：鎮痛薬、DMARD、コルチコステロイド、その他
  • 抗コクシジウム薬のグローバル市場（2021〜2031）：イオノフォア、合成薬
  • ブラストミセス症のグローバル市場（2021〜2031）：錠剤、軟膏、粉末、液体
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23MC087 )"オピオイド誘発性便秘症（OIC）治療薬のグローバル市場（2021～2031）：μオピオイド受容体拮抗薬、クロライドチャネル2活性剤、その他" (英文：Opioid Induced Constipation (OIC) Drugs Market By Drug Type (Mu-opioid Receptor Antagonists, Chloride Channel-2 Activators, Others), By Prescription Type (Over The Counter Drugs, Prescribed Drugs), By Distribution Channel (Hospital Pharmacies, Online Providers, Drug Store and Retail Pharmacies): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。